Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan plus pembrolizumab versus placebo plus pembrolizumab as adjuvant therapy after nephrectomy for clear cell renal cell carcinoma
CTR20220945Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) comparing Belzutifan plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Disease-free survival. Started Jun 2022; status: active.
02
Drugs
belzutifanpembrolizumab
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20220945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220945.